Back to Search
Start Over
Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection.
- Source :
-
Annals of hepatology [Ann Hepatol] 2022 Jan-Feb; Vol. 27 (1), pp. 100566. Date of Electronic Publication: 2021 Oct 22. - Publication Year :
- 2022
-
Abstract
- Introduction and Objectives: Sustained virologic response (SVR) is achieved in most cases of C-type liver disease after direct-acting antiviral (DAA) therapy. Although liver fibrosis improves, the degree of improvement is different. This study aimed to analyze the factors involved in improving liver fibrosis using the fibrosis 4 (FIB-4) index.<br />Material and Methods: Patients were monitored for >3 years after SVR. At the start of therapy (SOT), liver fibrosis was categorized as either mild (<1.45 n = 28), moderate (1.45-3.25 n = 139), or advanced (>3.25 n = 236) based on the FIB-4 index. The FIB-4 index in the advanced group decreased significantly compared to that of the other two, so we selected the advanced group as the analysis target. SOT and end of therapy (EOT) factors that contributed to the FIB-4 index ≤3.25 at 3 years after therapy were examined using a multivariate analysis.<br />Results: Among the SOT factors, age (<72 years old), absence of liver cirrhosis (LC), alanine transferase (ALT) (≥50 U/L), platelet (PLT) (≥10.2 × 10 <superscript>4</superscript> /mm <superscript>3</superscript> ), and total bilirubin (T.Bil) (<0.8 mg/dl) were the significant factors contributing to the improvement of the FIB-4 index. Among the EOT factors, age (<72 years), PLT (≥12.0 × 10 <superscript>4</superscript> /mm3), and hemoglobin (Hb) (≥12.1 g/dl) were the significant factors contributing to the improvement of FIB-4 index.<br />Conclusions: Factors involved in the improvement of liver fibrosis after SVR were young age, absence of LC, low T.Bil., high ALT, high PLT, and high Hb levels. The levels of T.Bil, PLT, and Hb were considered to be related to portal hypertension. Aging strongly impaired the improvement in liver fibrosis.<br />Competing Interests: Conflicts of interest The authors declare no conflicts of interest.<br /> (Copyright © 2021 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Disease Progression
Female
Follow-Up Studies
Hepatitis C, Chronic complications
Hepatitis C, Chronic virology
Humans
Liver Cirrhosis diagnosis
Liver Cirrhosis virology
Male
Middle Aged
Retrospective Studies
Young Adult
Aging
Antiviral Agents therapeutic use
Hepacivirus
Hepatitis C, Chronic drug therapy
Liver Cirrhosis etiology
Sustained Virologic Response
Subjects
Details
- Language :
- English
- ISSN :
- 1665-2681
- Volume :
- 27
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Annals of hepatology
- Publication Type :
- Academic Journal
- Accession number :
- 34688887
- Full Text :
- https://doi.org/10.1016/j.aohep.2021.100566